GHRP-1 is a synthetic peptide that stimulates growth hormone release by activating the ghrelin receptor, and has been studied for body composition, cardiac function, and cachexia in chronic illness.
What it does
GHRP-1 belongs to a class of compounds called growth hormone releasing peptides (GHRPs). These peptides work by binding to the GHSR1a receptor — the same receptor activated by ghrelin, the body's natural hunger and GH-release hormone. When GHSR1a is activated, the pituitary gland releases a pulse of growth hormone (GH) into the bloodstream PubMed 26811125. The structural core that makes this binding possible is a four-amino-acid sequence (Ala-Trp-D-Phe-Lys), and research into structure-activity relationships has shown which positions in the molecule matter most for receptor affinity PubMed 26811125.
Once GH is released, downstream effects include increased IGF-1 production (insulin-like growth factor 1, a key mediator of tissue growth and repair), shifts in body composition toward lean mass, and potential effects on cardiac and metabolic function PubMed 15951341. GHRP-1 and its metabolites remain active after administration — urinary excretion studies confirm that both the intact peptide and its breakdown products retain GHSR1a binding activity, which is relevant both for therapeutic use and for anti-doping detection PubMed 25869809.
What the evidence shows
Growth hormone secretion and body composition Solid mechanistic and receptor-binding data; limited controlled human trials
GHRP-1 reliably activates GHSR1a in receptor assays and produces measurable GH pulses. Structure-activity studies confirm its core binding sequence is among the more potent in the GHRP class PubMed 26811125. Nasal administration in human excretion studies demonstrated absorption and receptor-active metabolites in urine, confirming bioavailability beyond just injection routes PubMed 25869809. However, controlled human trials showing meaningful body composition changes specifically from GHRP-1 are sparse.
Cardiac function and cachexia in chronic illness Rodent evidence is solid; one human Phase II trial registered but results limited
In rats with heart failure, GHRPs including GHRP-1 reduced cardiomyocyte apoptosis (programmed cell death), improved cardiac output, and suppressed stress hormones, while also countering cachexia (the muscle and weight loss that accompanies chronic illness) PubMed 15951341. A Phase II randomized, double-blind, crossover trial in patients with end-stage renal disease (ESRD) on hemodialysis was registered to evaluate GHRP-1's safety, pharmacodynamics, and preliminary efficacy NCT00381602, but published outcome data from this trial are not widely available, leaving the human cardiac and cachexia evidence incomplete.
Anti-doping detection Strong analytical evidence in human urine samples
Multiple studies have mapped the urinary metabolite profiles of GHRP-1 and related peptides after nasal and other routes of administration PubMed 25869809, PubMed 23101768. GHRP-2 and GHRP-6 have been detected in athlete urine samples in real-world doping control settings PubMed 25809000, establishing that detection methods are viable. GHRP-1 itself is detectable via its intact form and active metabolites, which retain GHSR1a binding PubMed 26811125. This research is primarily forensic rather than therapeutic, but it confirms that GHRP-1 is absorbed, metabolized, and active in humans.
How it's used
In studies and self-reported protocols, GHRP-1 has been administered via subcutaneous injection (under the skin) and intranasally (as a nasal spray). The registered Phase II trial examined GHRP-1 in a gel formulation for hemodialysis patients NCT00381602. No standardized dosing protocol has been established in the published literature; dose, frequency, and timing vary across contexts. Anecdotally, GHRPs as a class are often administered two to three times daily, timed around fasting or sleep to coincide with natural GH pulses, but this is not specifically validated for GHRP-1 in controlled trials. Half-life and precise pharmacokinetic parameters have not been publicly reported for GHRP-1.
Side effects and safety
Side effects reported across the GHRP class and in self-reports for GHRP-1 include injection site reactions, mild headache, water retention, and joint stiffness at lower exposure levels. At higher doses or with chronic use, more significant effects include carpal tunnel-like symptoms, insulin resistance, lethargy, and edema. Chronic high-dose use of GH-stimulating compounds carries a risk of contributing to diabetes-like metabolic changes. GHRP-1 is contraindicated in active malignancy (GH can promote tumor growth), pregnancy, and critical illness. Relative cautions apply to people with diabetes mellitus or severe obesity, given the compound's effects on insulin sensitivity. Long-term safety in humans has not been formally studied, and the absence of published Phase III or long-term data means that chronic-use risks remain genuinely unknown.
Bottom line
GHRP-1 has a well-characterized mechanism and produces real GH secretion in humans, but clinical trial data specific to it are thin — most of what's known comes from receptor studies, rodent models, and metabolite detection work. It may have legitimate applications in cachexia or cardiac rehabilitation, but these remain under-studied. People considering it should weigh meaningful unknowns around long-term safety against outcomes that, in humans, are not yet well-documented.